ClinicalTrials.gg
CompletedNCT01334944Updated Jul 5, 2023Results posted

Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen

A Phase 4 interventional study of Intravenous ibuprofen in Pain and Fever, sponsored by Cumberland Pharmaceuticals. Completed at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-05.

Sponsored by Cumberland Pharmaceuticals · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.

Enrollment
29th of 86
150 · median 100
Started
2011
with 6 others
Phase 4
30 of 86
3 open now
Registered
21st of 86
by date
Lead sponsor
6 of 86
Cumberland Pharmaceuticals

Among the 86 studies testing ibuprofen in Pain, this one is the 29th largest by enrollment, is one of 7 that started in 2011, is one of 30 in phase 4, and was the 21st registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing ibuprofen in Pain, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the safety of a single dose of intravenous ibuprofen administered over 5-10 minutes for the treatment of fever or pain in the hospital setting.

03

Conditions studied

  • Pain
  • Fever

Browse trials for

Keywords

  • Pain
  • Fever
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pain: Patients with baseline Visual Analog Scale assessment >3, -and/or- Fever: Patients with temperature >101°F.

Exclusion criteria

Exclusion Criteria:

  1. Patients with inadequate IV access
  2. Patients \<18 years of age
  3. History or allergy or to any component of intravenous ibuprofen, aspirin (or aspirin related products) or non-steroidal anti-inflammatory drug (NSAIDs)
  4. Active hemorrhage or bleeding
  5. Pregnant or nursing
  6. Patients in the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery
  7. Inability to understand the requirements of the study, be willing to provide written (as evidenced by signature on an informed consent document approved by an Institutional Review Board [IRB]), and agree to abide by the study restrictions
  8. Refusal to provide written authorization for use and disclosure of protected health information
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Intravenous ibuprofen

    Intravenous ibuprofen (400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 5-10 minute Treatment Period.

    Drug: Intravenous ibuprofen

Interventions

  • 400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes

    Also known as: Caldolor

06

What researchers measure

Primary outcomes

  1. To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.

    The incidence of treatment-emergent serious adverse events occurring in the six hours following administration of the last dose of intravenous ibuprofen

    Time frame: 6 hours

  2. To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.

    The incidence of treatment-emergent adverse events occurring in the six hours following administration of intravenous ibuprofen.

    Time frame: 6 hours

  3. To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting

    The change from baseline to one hour post administration of intravenous ibuprofen in vitals sign assessments (Temperature)

    Time frame: 1 hour

  4. To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.

    The change from baseline to one hour post administration of intravenous ibuprofen in vital sign assessments (Heart Rate).

    Time frame: 1 hour

  5. To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.

    The change from baseline to one hour post administration of intravenous ibuprofen in vital sign assessments (Respiratory Rate).

    Time frame: 1 hour

  6. To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.

    The change from baseline to one hour post administration of intravenous ibuprofen in vital sign assessments (Systolic Blood Pressure).

    Time frame: 1 hour

  7. To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.

    The change from baseline to one hour post administration of intravenous ibuprofen in vital sign assessments (Diastolic Blood Pressure).

    Time frame: 1 hour

Secondary outcomes

  1. To Determine the Efficacy of a Single Dose of 400 mg Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever

    The change in temperature from baseline over the 4 hours following intravenous ibuprofen administration

    Time frame: 4 hours

  2. To Determine the Efficacy of a Single Dose of 800 mg Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Pain (Mild to Moderate or Moderate to Severe).

    The change in patient self-assessment of pain utilizing the visual analog scale (VAS) from baseline over the 4 hours following intravenous ibuprofen administration. The VAS is a continuous scale compromised of a horizontal line, one hundred millimeters in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between o and 100.

    Time frame: 4 hours

  3. To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain

    The incidence of treatment-emergent serious adverse events occurring through extended dosing.

    Time frame: 24 hours

  4. To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain

    The incidence of treatment-emergent adverse events occurring through extended dosing.

    Time frame: 24 hours

07

Results

Posted Jun 23, 2014

Participant flow

Adult patients in the hospital setting experiencing pain and/or fever.

Participant flow — Overall Study
MilestoneFeverPain
Started11139
Received singel dose196
Received multiple doses1043
Completed11139
Not completed00

Outcome measures

PrimaryTo Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.

The incidence of treatment-emergent serious adverse events occurring in the six hours following administration of the last dose of intravenous ibuprofen

Time frame:
6 hours
Reported as:
Number · Number of Serious Adverse Events
To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.
Number of Serious Adverse EventsFeverPain
To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.00
PrimaryTo Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.

The incidence of treatment-emergent adverse events occurring in the six hours following administration of intravenous ibuprofen.

Time frame:
6 hours
Reported as:
Number · Number of Events
To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.
Number of EventsFeverPain
To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.016
PrimaryTo Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting

The change from baseline to one hour post administration of intravenous ibuprofen in vitals sign assessments (Temperature)

Time frame:
1 hour
Reported as:
Mean · Degree Fahrenheit
To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting
Degree FahrenheitFeverPain
To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting-0.9 (-2.7 to 0.3)-0.1 (-3.2 to 1.6)
PrimaryTo Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.

The change from baseline to one hour post administration of intravenous ibuprofen in vital sign assessments (Heart Rate).

Time frame:
1 hour
Reported as:
Mean · Beats Per Minute
To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.
Beats Per MinuteFeverPain
To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.-2 (-16 to 8)-1 (-34 to 62)
PrimaryTo Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.

The change from baseline to one hour post administration of intravenous ibuprofen in vital sign assessments (Respiratory Rate).

Time frame:
1 hour
Reported as:
Mean · Breaths Per Minute
To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.
Breaths Per MinuteFeverPain
To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.-1 (-5 to 2)0 (-17 to 14)
PrimaryTo Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.

The change from baseline to one hour post administration of intravenous ibuprofen in vital sign assessments (Systolic Blood Pressure).

Time frame:
1 hour
Reported as:
Mean · mm Hg
To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.
mm HgFeverPain
To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.-8 (-56 to 16)-4 (-51 to 45)
PrimaryTo Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.

The change from baseline to one hour post administration of intravenous ibuprofen in vital sign assessments (Diastolic Blood Pressure).

Time frame:
1 hour
Reported as:
Mean · mm Hg
To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.
mm HgFeverPain
To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.-4 (-16 to 4)-3 (-49 to 41)
SecondaryTo Determine the Efficacy of a Single Dose of 400 mg Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever

The change in temperature from baseline over the 4 hours following intravenous ibuprofen administration

Time frame:
4 hours
Reported as:
Mean · Degree Fahrenheit
To Determine the Efficacy of a Single Dose of 400 mg Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever
Degree FahrenheitFever
To Determine the Efficacy of a Single Dose of 400 mg Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever-1.5 (-2.2 to -0.7)
SecondaryTo Determine the Efficacy of a Single Dose of 800 mg Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Pain (Mild to Moderate or Moderate to Severe).

The change in patient self-assessment of pain utilizing the visual analog scale (VAS) from baseline over the 4 hours following intravenous ibuprofen administration. The VAS is a continuous scale compromised of a horizontal line, one hundred millimeters in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between o and 100.

Time frame:
4 hours
Reported as:
Mean · units on a scale
To Determine the Efficacy of a Single Dose of 800 mg Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Pain (Mild to Moderate or Moderate to Severe).
units on a scalePain
To Determine the Efficacy of a Single Dose of 800 mg Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Pain (Mild to Moderate or Moderate to Severe).-27.1 (-33.5 to -20.7)
SecondaryTo Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain

The incidence of treatment-emergent serious adverse events occurring through extended dosing.

Time frame:
24 hours
Reported as:
Number · Number of Serious Adverse Events
To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain
Number of Serious Adverse EventsFeverPain
To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain01
SecondaryTo Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain

The incidence of treatment-emergent adverse events occurring through extended dosing.

Time frame:
24 hours
Reported as:
Number · Number of Events
To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain
Number of EventsFeverPain
To Determine the Safety of a Multiple Doses of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain014

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fever—0/11 (0%)0/11 (0%)
Pain—1/139 (0.7%)43/139 (30.9%)
Most frequent serious events
Most frequent serious events
EventFeverPain
HypotensionVascular disorders0/111/139
Most frequent other events
Showing 10 of 28
Most frequent other events
EventFeverPain
Infusion Site PainInjury, poisoning and procedural complications0/1122/139
FlatulenceGastrointestinal disorders0/118/139
NauseaGastrointestinal disorders0/115/139
Breath Sounds AbnormalInvestigations0/114/139
HyperglycaemiaMetabolism and nutrition disorders0/114/139
VomitingGastrointestinal disorders0/113/139
Anaemia PostoperativeInjury, poisoning and procedural complications0/113/139
PruritusSkin and subcutaneous tissue disorders0/113/139
HeadacheNervous system disorders0/112/139
TachycardiaCardiac disorders0/112/139

Baseline characteristics

Age, Customized
Age, Customized(years)Intravenous Ibuprofen
Greater than or equal to 18 years of age150
Sex: Female, Male
Sex: Female, Male(Participants)Intravenous Ibuprofen
Female91
Male59
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intravenous Ibuprofen
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander1
Black or African American34
White106
More than one race0
Unknown or Not Reported6
Region of Enrollment
Region of Enrollment(participants)Intravenous Ibuprofen
United States150
08

Study locations

13 sites
  • UCSD
    San Diego, California 92103, United States
  • Danbury
    Danbury, Connecticut 06810, United States
  • University of Miami - Miller School of Medicine
    Miami, Florida 33136, United States
  • Grady
    Atlanta, Georgia 30303, United States
  • Beth Israel Deaconnes MC
    Boston, Massachusetts 02215, United States
  • Columbia
    New York, New York 10032, United States
  • The University of North Carolina Hospitals
    Chapel Hill, North Carolina 27599, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • The Moses H. Cone Memorial Hospital
    Greensboro, North Carolina 27401-1020, United States
  • Wake Forest University Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Fairview
    Cleveland, Ohio 44111, United States
  • The Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Lankenau
    Wynnewood, Pennsylvania 19096, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Sep 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2011
First posted
Apr 13, 2011
Start
Jun 2011
Primary completionActual
Sep 2012
CompletionActual
Oct 2012
Results first posted
Jun 23, 2014
Last update
Jul 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01334944
Responsible party
Sponsor
First posted
Apr 13, 2011
Start date
Jun 2011
Primary completion
Sep 2012
Completion
Oct 2012
Results posted
Jun 23, 2014
Last update
Jul 5, 2023

Study contacts

Art P Wheeler, M.D.
study director · Cumberland Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion